 Cocrystal Pharma Inc NASDAQ: COCP has announced progress on its COVID-19 antiviral drug candidates that target coronaviruses, including SARS-CoV-2, and it also plans to launch a second COVID-19 program with additional antiviral compounds for development, apart from CDI-45205. The company said that it had designed new chemical scaffolds to improve in vitro potency and pharmacokinetic properties. 